GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...
New RSV vaccine guidelines: Adults 75+ urged to vaccinate
In 2023, the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) recommended ...
Analysis-GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...
Pfizer wins bid to invalidate GSK's patents over RSV vaccine
Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...
Making an RSV Vaccine Was Hard. Getting People to Take It Is Even Harder
RSV hospitalizes thousands of people in the US every year. Three new vaccines could help stem the spread, but there are ...
What you need to know about the new RSV vaccine
As the days grow cooler, families across Utah are reminded that respiratory viruses, particularly Respiratory Syncytial Virus ...
RSV can be deadly, especially for older adults. What to know about symptoms and the new vaccine
In most cases, adequate hydration and over-the-counter pain relievers can help manage your symptoms during the week or two it ...
Everything You Need to Know About Getting the RSV Vaccine During Pregnancy
If you, for some reason, don’t get the RSV vaccine while you’re pregnant, you can (and should!) still protect your baby after ...
What You Really Need to Know About the RSV Vaccine for Fall 2024
The CDC just released new recommendations for the shot in June 2024, focusing on folks that are 60 or older, who are ...
Low RSV and COVID vaccine usage is in line with investor expectations, but concerning: Jefferies
Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst says, and could mean weak earnings for ...
McKnight's Long-Term Care News5d
RSV vaccine still 43.3 percent effective 3 years after people take it, trial shows
GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...
BioPharma Dive5d
GSK says RSV vaccine protects against disease over three seasons
Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.